Are Peptides Legal in the US? Current FDA Status and What’s Changing

In the United States, most peptides are not controlled substances – but selling them for human use without FDA approval is illegal. That single sentence captures the core tension in US peptide law, and nearly everything else flows from it.

The answer to “are peptides legal?” depends entirely on which peptide, how it is classified, how it is manufactured, and what it is being sold for. Some peptides are FDA-approved prescription drugs used in hospitals every day. Others sit on a restricted list that prohibits licensed pharmacies from compounding them. Others still are sold online as “research chemicals” under a regulatory framework the FDA has made clear it considers inadequate.

The FDA regulates peptides through several overlapping frameworks, and where a peptide sits within these frameworks determines its legal status.

FDA-Approved Prescription Drugs

Peptides that have completed the full New Drug Application (NDA) or Biologics License Application (BLA) process are legal prescription medications. These include semaglutide (marketed as Ozempic and Wegovy), tirzepatide (Mounjaro and Zepbound), and tesamorelin (Egrifta). They are prescribed by physicians, dispensed by licensed pharmacies, and covered by insurance for approved indications. There is no legal ambiguity here.

Compounded Medications Under Section 503A and 503B

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) allows state-licensed pharmacies to compound drug products using bulk drug substances for individual patients with valid prescriptions, provided the substance either has a USP/NF monograph, is a component of an FDA-approved drug, or appears on the FDA’s 503A Bulks List. Section 503B covers outsourcing facilities that can compound at larger scale under direct FDA oversight and cGMP standards.

This is the pathway that matters most for peptides like BPC-157, TB-500, and ipamorelin. Most of these compounds have no USP monograph and are not components of any approved drug. That means their only route to legal compounding is inclusion on the 503A Bulks List – which is governed by the FDA’s category system. The FDA assigns proposed substances to Category 1 (compounding permitted), Category 2 (restricted due to safety concerns) or Category 3 (insufficient information). For a detailed explanation of how the categories work and the differences between 503A and 503B pharmacies, see our Category 1 vs Category 2 guide.

In September 2023, the FDA placed 19 widely used peptides on Category 2, ending legal compounding access virtually overnight. That decision triggered lawsuits, a change in political direction under HHS Secretary Kennedy, and ultimately the removal of 12 of those peptides from Category 2 in April 2026.

Removal from Category 2 does not mean these peptides can be legally compounded. They currently exist in a regulatory grey zone: no longer explicitly prohibited, but not yet explicitly authorised. The US operates on a positive-list system – to be compounded lawfully, a substance must appear on Category 1, have a USP/NF monograph, or be a component of an approved drug. These peptides meet none of those criteria. This positive-list structure is unique to the US and is the reason removal from the restricted list is not the same as approval.

Seven of the removed peptides (BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax and Epitalon) are scheduled for PCAC review on 23-24 July 2026. Five more (including GHK-Cu and Melanotan II) are deferred to a second session before February 2027. For the full timeline from restriction to reclassification, including which peptides remain restricted and which were previously rejected, see our reclassification tracker.

A significant volume of peptide sales in the US has historically occurred through vendors selling compounds labelled “for research use only” (RUO) or “not for human consumption.” The legal theory behind this model is that selling a chemical reagent for legitimate laboratory research is lawful, provided no therapeutic claims are made and the product is not marketed for human use. The scale of this market is substantial – US Customs data shows Chinese peptide imports to the US reached $328 million in 2025, roughly double the prior year, while online peptide advertising increased by 678% between 2022 and 2025.

The FDA’s position on this model has become increasingly hostile. The agency has described RUO disclaimers as “a ruse to avoid FDA scrutiny for selling misbranded and adulterated products.” Enforcement has targeted vendors where evidence suggests the products were actually intended for human use – for example, where websites included dosing information, sold products alongside syringes and bacteriostatic water, or made therapeutic claims even implicitly.

The Crackdown Timeline

FDA regulatory pressure on peptide vendors has escalated sharply since late 2024, progressing from written notices to physical raids to criminal referrals:

• December 2024: FDA issues formal compliance notices to four vendors – Prime Peptides, Xcel Peptides, SwissChems, and Summit Research – for selling semaglutide, tirzepatide, and retatrutide as unapproved drugs
• Mid-2025: The crackdown moves from written notices to warehouse raids, including the seizure of operations at Amino Asylum
• September 2025: Over 50 regulatory actions issued in a single batch targeting GLP-1 compounders, with confirmed DOJ involvement
• November 2025: Alabama obtains a temporary restraining order against GLP-1 distributors – the first state-level injunctive relief in the peptide regulatory space
• March 2026: Peptide Sciences, widely considered the largest grey-market peptide vendor in the US with an estimated $7.4 million in monthly sales, ceases operations. Another 7 vendor websites receive FDA regulatory notices on a single day

According to FDA regulatory tracking data, the agency issued over 175 regulatory letters by early 2026, with 43 directly involving peptides or compounded GLP-1 compounds – up from just 14 across all of 2024. Scrutiny has expanded beyond the federal level: state pharmacy boards have begun independent investigations of med spas and clinics offering unapproved peptide therapies, and state-level litigation has created additional legal exposure for distributors.

An important distinction often lost in public discussion: most peptides are not DEA-scheduled controlled substances under the Controlled Substances Act. They are not in the same legal category as opioids, anabolic steroids, or stimulants. FDA action against peptide vendors proceeds under the FD&C Act framework – specifically, the provisions governing unapproved new drugs and misbranded products – not under drug scheduling law.

This means that personal possession of most peptides is not itself a criminal offence under federal law. The legal risk concentrates overwhelmingly on the supply side – manufacturing, importing, distributing, and selling peptides as unapproved drugs. However, this should not be confused with a legal endorsement of purchasing grey-market peptides. Products from unregulated sources carry genuine safety risks including incorrect dosing, contamination, and mislabelled compounds.

Semaglutide and tirzepatide occupy a distinct regulatory position from compounds like BPC-157 or TB-500. Both are FDA-approved prescription drugs. They were never placed on the Category 2 list. Their compounding availability has been governed by separate drug shortage declarations and regulatory discretion timelines.

The FDA declared the semaglutide shortage resolved in February 2025, which ended the enforcement discretion that had allowed 503A pharmacies to compound it. The legal landscape for compounded GLP-1 peptides continues to evolve through litigation, including lawsuits filed by Eli Lilly against telehealth companies distributing tirzepatide and by Novo Nordisk against semaglutide distributors. For detailed coverage of these compounds, see our guides to semaglutide and tirzepatide.

The US regulatory approach to peptides sits between the relatively permissive UK framework and the highly restrictive Australian system. In the United Kingdom, most research peptides are unscheduled and can be legally sold for research purposes, with regulatory attention focused on sellers who make therapeutic claims. In Australia, the TGA takes a far stricter approach, classifying compounds like BPC-157 under Schedule 4 (prescription-only) and melanotan II under Schedule 9 (prohibited), with border seizures and prosecutions actively pursued.

The US system is unique in that it has an active compounding pathway (503A/503B) that, when a peptide is on the Category 1 list, provides a legitimate, prescription-based route to access. No other major English-speaking country has an equivalent system. This is why the category system and the PCAC review process matter so much – they are the mechanism through which peptides can move from regulatory limbo into a structured, legal compounding framework.

FDA-approved peptide drugs like semaglutide and tirzepatide are fully legal with a prescription. Peptides on the 503A Category 1 list can be legally prepared by licensed compounding pharmacies with a valid prescription. Peptides recently removed from Category 2 – including BPC-157, TB-500, and MOTs-C – exist in a regulatory grey zone pending PCAC review and cannot yet be lawfully compounded. Peptides sold as “research use only” exist under an increasingly hostile regulatory regime, with FDA actions escalating from notices to raids to criminal referrals. State law may impose additional restrictions beyond the federal framework. No compounded or research-use peptide carries FDA approval for safety, efficacy, or quality.